Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
KalVista
Biotech
KalVista sells Japanese rights for HAE drug to Kaken
As KalVista waits for an FDA decision on sebetralstat, the company has sold the Japanese rights to Kaken for $11 million upfront.
James Waldron
Apr 8, 2025 8:35am
KalVista's persistence with sebetralstat pays off in ph. 3 win
Feb 13, 2024 6:30am
KalVista axes angioedema program over raised enzyme levels
Oct 4, 2022 10:32am
KalVista bulks up executive team with CMO addition
May 3, 2021 8:00am
KalVista hit with a clinical hold on 2nd asset
Apr 20, 2021 8:05am
KalVista's rival to Firazyr aces trial, sending stock up 200%
Feb 9, 2021 8:25am
